Results 71 to 80 of about 1,443,667 (357)
Development of a Bispecific Antibody Targeting CD30 and CD137 on Hodgkin and Reed-Sternberg Cells
Frontiers in Oncology, 2019 Hodgkin Lymphoma (HL) is a malignancy that frequently affects young adults. Although, there are effective treatments not every patient responds, necessitating the development of novel therapeutic approaches, especially for relapsed and refractory cases ...
Sakthi Rajendran +11 more
doaj +1 more source
xTrimoABFold: De novo Antibody Structure Prediction without MSA [PDF]
arXiv, 2022 In the field of antibody engineering, an essential task is to design a novel antibody whose paratopes bind to a specific antigen with correct epitopes. Understanding antibody structure and its paratope can facilitate a mechanistic understanding of its function.
arxiv
Chemical generation of bispecific antibodies [PDF]
Proceedings of the National Academy of Sciences, 2010 Bispecific antibodies (BsAbs) are regarded as promising therapeutic agents due to their ability to simultaneously bind two different antigens. Several bispecific modalities have been developed, but their utility is limited due to problems with stability and manufacturing complexity.
Jie Huang +21 more
openaire +3 more sources
Circulating tumor cells: advancing personalized therapy in small cell lung cancer patients
Molecular Oncology, EarlyView.Small cell lung cancer (SCLC) is an aggressive form of lung cancer that spreads rapidly to secondary sites such as the brain and liver. Cancer cells circulating in the blood, “circulating tumor cells” (CTCs), have demonstrated prognostic value in SCLC, and evaluating biomarkers on CTCs could guide treatment decisions such as for PARP inhibitors ...
Prajwol Shrestha +6 more
wiley +1 more source
Global Challenges, Volume 7, Issue 1, January 2023., 2023 Combining oncolytic viruses with anti‐checkpoint antibodies such as anti‐PD‐1, anti‐PDL‐1, and anti‐CTLA4 or CAR‐T cells can be effective in cancer therapy in a synergistic fashion. Oncolytic virotherapy induces the expression of PD‐1 and PDL‐1 in the tumor microenvironment components. Virotherapy promotes the infiltration of CD4+ and CD8+ T cells into
Hai Zou, Xiao‐Zhou Mou, Biao Zhu
wiley +1 more source
mAbs, 2022 As the current biotherapeutic market is dominated by antibodies, the design of different antibody formats, like bispecific antibodies, is critical to the advancement of the field.
Monica L. Fernández-Quintero +5 more
doaj +1 more source
On Pre-trained Language Models for Antibody [PDF]
arXiv, 2023 Antibodies are vital proteins offering robust protection for the human body from pathogens. The development of general protein and antibody-specific pre-trained language models both facilitate antibody prediction tasks. However, there have been limited studies that comprehensively explore the representation capability of distinct pre-trained language ...
arxiv
Cancer Discovery, 2021 The clinical benefit of PD-1 blockade can be improved by combination with CTLA-4 inhibition but is commensurate with significant irAEs sub-optimally limiting the doses of anti-CTLA-4 mAb that can be used.
S. Dovedi +34 more
semanticscholar +1 more source
FEBS Open Bio, EarlyView.Novel mAbs could detect cancer‐associated membrane proteins on various type of pancreatic ductal adenocarcinomas (PDAC) by flow cytometry with viable PDAC cells and by immunohistochemistry with PDAC tissues. Results of protein expression were substantiated by mRNA expression by The Cancer Genome Atlas.
Takashi Nakano +16 more
wiley +1 more source
Hematological Oncology, Volume 40, Issue 5, Page 987-998, December 2022., 2022 Abstract The treatment scenario for newly‐diagnosed transplant‐ineligible multiple myeloma patients (NEMM) is quickly evolving. Currently, combinations of proteasome inhibitors and/or immunomodulatory drugs +/− the monoclonal antibody Daratumumab are used for first‐line treatment, even if head‐to‐head comparisons are lacking.
Cirino Botta +17 more
wiley +1 more source